# Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

> **NCT03377491** · PHASE3 · COMPLETED · sponsor: **NovoCure Ltd.** · enrollment: 571 (actual)

## Conditions studied

- Pancreas Adenocarcinoma

## Interventions

- **DEVICE:** NovoTTF-200T
- **DRUG:** Gemcitabine
- **DRUG:** nab paclitaxel

## Key facts

- **NCT ID:** NCT03377491
- **Lead sponsor:** NovoCure Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-10
- **Primary completion:** 2024-10-16
- **Final completion:** 2024-10-16
- **Target enrollment:** 571 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03377491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03377491, "Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03377491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*